CTNNB1 and Miyoshi myopathy: Similar to other, more frequent hotspot mutations in MM (BRAFV600 and NRASQ61) [14–16], expression of these low-frequency APC/CTNNB1 mutations may have an adverse prognosis, in part due to the development of brain metastases, but does not mitigate the clinical benefit from immunotherapies.